Letermovir
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cytomegalovirus Infections
Conditions
Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
Trial Timeline
Aug 8, 2024 → Sep 1, 2026
NCT ID
NCT06407232About Letermovir
Letermovir is a phase 3 stage product being developed by Merck for Cytomegalovirus Infections. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06407232. Target conditions include Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07199465 | Phase 1 | Recruiting |
| NCT06407232 | Phase 3 | Recruiting |
| NCT05789615 | Pre-clinical | Completed |
| NCT05763823 | Phase 3 | Completed |
| NCT04904614 | Approved | Completed |
| NCT04312841 | Phase 2 | Completed |
| NCT03728426 | Phase 2 | Completed |
Competing Products
20 competing products in Cytomegalovirus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 52 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 52 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 1 | 33 |
| Letermovir | Merck | Approved | 85 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 52 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 33 |
| Ganciclovir | Merck | Pre-clinical | 23 |
| Letermovir + Placebo | Merck | Phase 3 | 77 |
| Letermovir | Merck | Phase 2 | 52 |
| V160 + Placebo | Merck | Phase 2 | 52 |
| V160 | Merck | Phase 1 | 33 |
| Letermovir | Merck | Phase 3 | 77 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Zidovudine + Didanosine + Ganciclovir | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Pre-clinical | 23 |
| Foscarnet sodium + Ganciclovir | Roche | Phase 1 | 33 |
| Valganciclovir + Valganciclovir | Roche | Phase 3 | 77 |